Diligence memo · auto-generated · as of July 2, 2026
Bioscience Pharma Partners, LLC
Bioscience Pharma Partners, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Bioscience Pharma Partners, LLC operates in Pharmaceuticals, based in SCOTTSDALE.
Sub-sector tags: biotech, pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Bioscience Pharma Partners, LLC has raised $2.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.5M on 2018-03-20.
Most recent recorded round closed around 2018-03-20.
Valuation (modeled)modeled
Provath models Bioscience Pharma Partners, LLC at approximately $95M (range $1.9M–$746M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.58× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Last raise 8.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 31% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: Chase Therapeutics Corp, Acura Pharmaceuticals, Inc, Paragon Biosciences Skyline Capital, LLC, Phoenix PharmaLabs Inc, Saghmos Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.